Tumor Necrosis Factor Inhibitor Drugs Market

Tumor Necrosis Factor Inhibitor Drugs Market Size, Share, Growth Analysis, By Product(Humira, Enbrel), By Sales Channel(Hospital Pharmacies, Specialty Pharmacies), By Regional(North America, U.S.) - Industry Forecast 2023-2030


Report ID: UCMIG35I2235 | Region: Global | Published Date: Upcoming |
Pages: 165 | Tables: 55 | Figures: 60

Tumor Necrosis Factor Inhibitor Drugs Market Insights

Market Overview:

Evidencing an initial worth of USD 40.4 billion in 2018, the global market for tumor necrosis factor inhibitor drugs has set its course for progression, with an anticipated Compound Annual Growth Rate (CAGR) of 0.5% throughout the forecast period. This ascent is propelled by a confluence of factors, notably including the introduction of novel product offerings and a promising pipeline of developments. A compelling catalyst in this trajectory is the escalating prevalence of autoimmune diseases, effectively augmenting the demand for effective treatment solutions like TNF inhibitor drugs. As a corollary, a marked upswing in public awareness regarding Tumor Necrosis Factor (TNF) and its implications is further fostering the market's expansion. Collectively, these dynamics harmonize to underscore a positive outlook for the tumor necrosis factor inhibitor drugs sector.

Tumor Necrosis Factor Inhibitor Drugs Market, Forecast & Y-O-Y Growth Rate, 2020 - 2028
ForecastGrowthRate
To get more reports on the above market click here to
GET FREE SAMPLE

This report is being written to illustrate the market opportunity by region and by segments, indicating opportunity areas for the vendors to tap upon. To estimate the opportunity, it was very important to understand the current market scenario and the way it will grow in future.

Production and consumption patterns are being carefully compared to forecast the market. Other factors considered to forecast the market are the growth of the adjacent market, revenue growth of the key market vendors, scenario-based analysis, and market segment growth.

The market size was determined by estimating the market through a top-down and bottom-up approach, which was further validated with industry interviews. Considering the nature of the market we derived the Pharmaceuticals by segment aggregation, the contribution of the Pharmaceuticals in Pharmaceuticals, Biotechnology & Life Sciences and vendor share.

To determine the growth of the market factors such as drivers, trends, restraints, and opportunities were identified, and the impact of these factors was analyzed to determine the market growth. To understand the market growth in detail, we have analyzed the year-on-year growth of the market. Also, historic growth rates were compared to determine growth patterns.

Segmentation Analysis:

The Tumor Necrosis Factor Inhibitor Drugs Market is segmented by Product, Sales Channel, Regional. We are analyzing the market of these segments to identify which segment is the largest now and in the future, which segment has the highest growth rate, and the segment which offers the opportunity in the future.

Tumor Necrosis Factor Inhibitor Drugs Market Basis Point Share Analysis, 2021 Vs. 2028
BasisPointShareAnalysis
To get detailed analysis on all segments
BUY NOW
  • Based on Product the market is segmented as, Humira, Enbrel, Remicade, Simponi/Simponi Aria, Cimzia, Biosimilars, Application, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis, Hidradenitis Suppurativa, Others
  • Based on Sales Channel the market is segmented as, Hospital Pharmacies, Specialty Pharmacies, Online Pharmacies
  • Based on Regional the market is segmented as, North America, U.S., Canada, Europe, U.K., Germany, Spain, France, Italy, Asia Pacific, Japan, China, India, South Korea, Australia, Latin America, Brazil, Mexico, Argentina, Middle East & Africa, South Africa, Saudi Arabia, UAE, KEY MARKET PLAYERS, AbbVie Inc., Amgen Inc., Johnson & Johnson Services, Inc., UCB S.A., Novartis International AG, Pfizer, Inc., Merck & co., Inc.

Regional Analysis:

Tumor Necrosis Factor Inhibitor Drugs Market is being analyzed by North America, Europe, Asia-Pacific (APAC), Latin America (LATAM), Middle East & Africa (MEA) regions. Key countries including the U.S., Canada, Germany, France, UK, Italy, Spain, China, India, Japan, Brazil, GCC Countries, and South Africa among others were analyzed considering various micro and macro trends.

Tumor Necrosis Factor Inhibitor Drugs Market Attractiveness Analysis, By Region 2020-2028
AttractivenessAnalysis
To know more about the market opportunities by region and country, click here to
REQUEST FREE CUSTOMIZATION

Tumor Necrosis Factor Inhibitor Drugs Market : Risk Analysis

SkyQuest's expert analysts have conducted a risk analysis to understand the impact of external extremities on Tumor Necrosis Factor Inhibitor Drugs Market. We analyzed how geopolitical influence, natural disasters, climate change, legal scenario, economic impact, trade & economic policies, social & ethnic concerns, and demographic changes might affect Tumor Necrosis Factor Inhibitor Drugs Market's supply chain, distribution, and total revenue growth.

Competitive landscaping:

To understand the competitive landscape, we are analyzing key Tumor Necrosis Factor Inhibitor Drugs Market vendors in the market. To understand the competitive rivalry, we are comparing the revenue, expenses, resources, product portfolio, region coverage, market share, key initiatives, product launches, and any news related to the Tumor Necrosis Factor Inhibitor Drugs Market.

To validate our hypothesis and validate our findings on the market ecosystem, we are also conducting a detailed porter's five forces analysis. Competitive Rivalry, Supplier Power, Buyer Power, Threat of Substitution, and Threat of New Entry each force is analyzed by various parameters governing those forces.

Key Players Covered in the Report:

  • sights
  • The global tumor necrosis factor inhibitor drugs market size was valued at USD 40.4 billion in 2018 and is estimated to expand at a CAGR of 0.5% over the forecast period. The growth is expected to be driven by new product launches, promising pipeline, increasing incidence of autoimmune diseases, and a significant rise in consumer awareness regarding Tumor Necrosis Factor (TNF).
  • TNF inhibitors are used to suppress the inflammatory response caused by TNF cytokines and hence are used for the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, Crohn’s disease, and cancer among others. The role of TNF inhibitors in the treatment of metastatic melanomas and locally advanced soft tissue sarcomas is under investigation.
  • The biologics in TNF inhibitor market face a direct internal threat from biosimilars. Loss of patent exclusivities in various regions pave the way for biosimilars. In addition, the market is engaged in an intense competitive rivalry with Interleukin (IL) inhibitors. IL inhibitors have been proven to have improved safety and efficacy profiles and demonstrate superior results in several head-to-head clinical trials.
  • A significant paradigm shift in the treatment of autoimmune diseases, driven by the targeted action of biologics and the emergence of biosimilars has been observed. However, the consumer demand for cost-effective medicines with improved safety and efficacy profiles is likely to have a positive impact on market dynamics.
  • Product Insights
  • Humira led the product segment in 2018, capturing nearly half the revenue share. Humira generated USD 19.9 billion in 2018 and continues to be one of the top-selling pharmaceutical products in the world. Although Humira’s patent expired in Europe in 2018, the product retains its patent exclusivity in U.S. until 2023. The loss of patent exclusivity is likely to result in declining sales; however, Humira is projected to be at top of the TNF inhibitor products through to 2026.
  • The wave of biosimilars poses a serious threat to biologics, supported by their cost-effectiveness and comparable results in head-to-head clinical trials. Several biosimilar versions of Humira, Enbrel, and Remicade have been launched. Some of the key biosimilar products included in this research are Erelzi, Inflectra/Remsima, Cyltezo, Renflexis/Flixabi, Ifixi/Zessly, Hyrimoz, and Amjevita/Amgevita.
  • Application Insights
  • Autoimmune disease segment accounts for a majority of the market share, although the medicines are being tested for other indications, such as cancer. Rheumatoid arthritis led the application segment in 2018, capturing more than 17% of the overall revenue share. The segment is driven by a high treatment rate and product penetration for the treatment of rheumatoid arthritis.
  • Psoriasis and psoriatic arthritis are estimated to be the fastest growing application segments through the forecast period. Psoriasis market is driven by increasing disease prevalence, consumer awareness supported by awareness campaigns held by several public and private organizations, and favorable reimbursement policies.
  • Sales Channel Insights
  • TNF inhibitor drugs are commercialized through three sales channels, namely, hospital pharmacies, specialty pharmacies, and online pharmacies. Hospital pharmacies accounted for the largest market share in 2018, majorly driven by the high patient turnover in hospitals.
  • Most biologics and biosimilars are sold at specialty pharmacies, rather than retail pharmacies. One of the major advantages offered by specialty pharmacies is that they provide disease-specific care plans, customized for each patient, thus addressing financial constraints as well as delivering better outcomes.
  • Regional Insights
  • North America led the regional landscape in 2018, owing to strong commercial sales of TNF inhibitors in U.S. Some of the other factors contributing to the growth include the presence of key manufacturers, proactive government initiatives, favorable reimbursement policies, and a large patient pool.
  • Asia Pacific is estimated to be one of the fastest growing regions, over the forecast period. The trend of biosimilars in the emerging markets, such as China, India, and South Korea, is a key regional growth driver. In addition, the overall economic development, improvement in healthcare infrastructure, increase in disposable income, and rise in consumer awareness are likely to contribute to the regional demand.
  • Tumor Necrosis Factor Inhibitor Drugs Market Share Insights
  • As regulatory procedures become more stringent and competitive rivalry intensifies, new products must have a significant clinical advantage over existing products, in terms of safety and efficacy or the end result. This has led to a large number of head-to-head trials between key commercial products, such as Humira and Remicade, and new products or late-stage pipeline candidates. These trials determine the superiority of performance through a comparative analysis of several parameters.
  • KEY MARKET SEGMENTS:
  • By Product
  • Humira
  • Enbrel
  • Remicade
  • Simponi/Simponi Aria
  • Cimzia
  • Biosimilars
  • Application
  • Rheumatoid Arthritis
  • Psoriasis
  • Psoriatic Arthritis
  • Crohn’s Disease
  • Ulcerative Colitis
  • Ankylosing Spondylitis
  • Juvenile Idiopathic Arthritis
  • Hidradenitis Suppurativa
  • Others
  • By Sales Channel
  • Hospital Pharmacies
  • Specialty Pharmacies
  • Online Pharmacies
  • By Regional
  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • Spain
  • France
  • Italy
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • KEY MARKET PLAYERS
  • AbbVie Inc.
  • Amgen Inc.
  • Johnson & Johnson Services, Inc.
  • UCB S.A.
  • Novartis International AG
  • Pfizer, Inc.
  • Merck & co., Inc.

SkyQuest's Expertise:

The Tumor Necrosis Factor Inhibitor Drugs Market is being analyzed by SkyQuest's analysts with the help of 20+ scheduled Primary interviews from both the demand and supply sides. We have already invested more than 250 hours on this report and are still refining our date to provide authenticated data to your readers and clients. Exhaustive primary and secondary research is conducted to collect information on the market, peer market, and parent market.

Our cross-industry experts and revenue-impact consultants at SkyQuest enable our clients to convert market intelligence into actionable, quantifiable results through personalized engagement.

Scope Of Report

Report Attribute Details
The base year for estimation 2021
Historical data 2016 – 2022
Forecast period 2022 – 2028
Report coverage Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis
Segments covered
  • By Product - Humira, Enbrel, Remicade, Simponi/Simponi Aria, Cimzia, Biosimilars, Application, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis, Hidradenitis Suppurativa, Others
  • By Sales Channel - Hospital Pharmacies, Specialty Pharmacies, Online Pharmacies
  • By Regional - North America, U.S., Canada, Europe, U.K., Germany, Spain, France, Italy, Asia Pacific, Japan, China, India, South Korea, Australia, Latin America, Brazil, Mexico, Argentina, Middle East & Africa, South Africa, Saudi Arabia, UAE, KEY MARKET PLAYERS, AbbVie Inc., Amgen Inc., Johnson & Johnson Services, Inc., UCB S.A., Novartis International AG, Pfizer, Inc., Merck & co., Inc.
Regional scope North America, Europe, Asia-Pacific (APAC), Latin America (LATAM), Middle East & Africa (MEA)
Country scope U.S., Canada, Germany, France, UK, Italy, Spain, China, India, Japan, Brazil, GCC Countries, South Africa
Key companies profiled
  • sights
  • The global tumor necrosis factor inhibitor drugs market size was valued at USD 40.4 billion in 2018 and is estimated to expand at a CAGR of 0.5% over the forecast period. The growth is expected to be driven by new product launches, promising pipeline, increasing incidence of autoimmune diseases, and a significant rise in consumer awareness regarding Tumor Necrosis Factor (TNF).
  • TNF inhibitors are used to suppress the inflammatory response caused by TNF cytokines and hence are used for the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, Crohn’s disease, and cancer among others. The role of TNF inhibitors in the treatment of metastatic melanomas and locally advanced soft tissue sarcomas is under investigation.
  • The biologics in TNF inhibitor market face a direct internal threat from biosimilars. Loss of patent exclusivities in various regions pave the way for biosimilars. In addition, the market is engaged in an intense competitive rivalry with Interleukin (IL) inhibitors. IL inhibitors have been proven to have improved safety and efficacy profiles and demonstrate superior results in several head-to-head clinical trials.
  • A significant paradigm shift in the treatment of autoimmune diseases, driven by the targeted action of biologics and the emergence of biosimilars has been observed. However, the consumer demand for cost-effective medicines with improved safety and efficacy profiles is likely to have a positive impact on market dynamics.
  • Product Insights
  • Humira led the product segment in 2018, capturing nearly half the revenue share. Humira generated USD 19.9 billion in 2018 and continues to be one of the top-selling pharmaceutical products in the world. Although Humira’s patent expired in Europe in 2018, the product retains its patent exclusivity in U.S. until 2023. The loss of patent exclusivity is likely to result in declining sales; however, Humira is projected to be at top of the TNF inhibitor products through to 2026.
  • The wave of biosimilars poses a serious threat to biologics, supported by their cost-effectiveness and comparable results in head-to-head clinical trials. Several biosimilar versions of Humira, Enbrel, and Remicade have been launched. Some of the key biosimilar products included in this research are Erelzi, Inflectra/Remsima, Cyltezo, Renflexis/Flixabi, Ifixi/Zessly, Hyrimoz, and Amjevita/Amgevita.
  • Application Insights
  • Autoimmune disease segment accounts for a majority of the market share, although the medicines are being tested for other indications, such as cancer. Rheumatoid arthritis led the application segment in 2018, capturing more than 17% of the overall revenue share. The segment is driven by a high treatment rate and product penetration for the treatment of rheumatoid arthritis.
  • Psoriasis and psoriatic arthritis are estimated to be the fastest growing application segments through the forecast period. Psoriasis market is driven by increasing disease prevalence, consumer awareness supported by awareness campaigns held by several public and private organizations, and favorable reimbursement policies.
  • Sales Channel Insights
  • TNF inhibitor drugs are commercialized through three sales channels, namely, hospital pharmacies, specialty pharmacies, and online pharmacies. Hospital pharmacies accounted for the largest market share in 2018, majorly driven by the high patient turnover in hospitals.
  • Most biologics and biosimilars are sold at specialty pharmacies, rather than retail pharmacies. One of the major advantages offered by specialty pharmacies is that they provide disease-specific care plans, customized for each patient, thus addressing financial constraints as well as delivering better outcomes.
  • Regional Insights
  • North America led the regional landscape in 2018, owing to strong commercial sales of TNF inhibitors in U.S. Some of the other factors contributing to the growth include the presence of key manufacturers, proactive government initiatives, favorable reimbursement policies, and a large patient pool.
  • Asia Pacific is estimated to be one of the fastest growing regions, over the forecast period. The trend of biosimilars in the emerging markets, such as China, India, and South Korea, is a key regional growth driver. In addition, the overall economic development, improvement in healthcare infrastructure, increase in disposable income, and rise in consumer awareness are likely to contribute to the regional demand.
  • Tumor Necrosis Factor Inhibitor Drugs Market Share Insights
  • As regulatory procedures become more stringent and competitive rivalry intensifies, new products must have a significant clinical advantage over existing products, in terms of safety and efficacy or the end result. This has led to a large number of head-to-head trials between key commercial products, such as Humira and Remicade, and new products or late-stage pipeline candidates. These trials determine the superiority of performance through a comparative analysis of several parameters.
  • KEY MARKET SEGMENTS:
  • By Product
  • Humira
  • Enbrel
  • Remicade
  • Simponi/Simponi Aria
  • Cimzia
  • Biosimilars
  • Application
  • Rheumatoid Arthritis
  • Psoriasis
  • Psoriatic Arthritis
  • Crohn’s Disease
  • Ulcerative Colitis
  • Ankylosing Spondylitis
  • Juvenile Idiopathic Arthritis
  • Hidradenitis Suppurativa
  • Others
  • By Sales Channel
  • Hospital Pharmacies
  • Specialty Pharmacies
  • Online Pharmacies
  • By Regional
  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • Spain
  • France
  • Italy
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • KEY MARKET PLAYERS
  • AbbVie Inc.
  • Amgen Inc.
  • Johnson & Johnson Services, Inc.
  • UCB S.A.
  • Novartis International AG
  • Pfizer, Inc.
  • Merck & co., Inc.
Customization scope Free report customization (15% Free customization) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options Reap the benefits of customized purchase options to fit your specific research requirements.

Objectives of the Study

  • To forecast the market size, in terms of value, for various segments with respect to five main regions, namely, North America, Europe, Asia-Pacific (APAC), Latin America (LATAM), Middle East & Africa (MEA)
  • To provide detailed information regarding the major factors influencing the growth of the Market (drivers, restraints, opportunities, and challenges)
  • To strategically analyze the micro markets with respect to the individual growth trends, future prospects, and contribution to the total market
  • To provide a detailed overview of the value chain and analyze market trends with the Porter's five forces analysis
  • To analyze the opportunities in the market for various stakeholders by identifying the high-growth Segments
  • To identify the key players and comprehensively analyze their market position in terms of ranking and core competencies, along with detailing the competitive landscape for the market leaders
  • To analyze competitive development such as joint ventures, mergers and acquisitions, new product launches and development, and research and development in the market

What does this Report Deliver?

  • Market Estimation for 20+ Countries
  • Historical data coverage: 2016 to 2022
  • Growth projections: 2022 to 2028
  • SkyQuest's premium market insights: Innovation matrix, IP analysis, Production Analysis, Value chain analysis, Technological trends, and Trade analysis
  • Customization on Segments, Regions, and Company Profiles
  • 100+ tables, 150+ Figures, 10+ matrix
  • Global and Country Market Trends
  • Comprehensive Mapping of Industry Parameters
  • Attractive Investment Proposition
  • Competitive Strategies Adopted by Leading Market Participants
  • Market drivers, restraints, opportunities, and its impact on the market
  • Regulatory scenario, regional dynamics, and insights of leading countries in each region
  • Segment trends analysis, opportunity, and growth
  • Opportunity analysis by region and country
  • Porter's five force analysis to know the market's condition
  • Pricing analysis
  • Parent market analysis
  • Product portfolio benchmarking

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Tumor Necrosis Factor Inhibitor Drugs Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Tumor Necrosis Factor Inhibitor Drugs Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)
  • sights
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • The global tumor necrosis factor inhibitor drugs market size was valued at USD 40.4 billion in 2018 and is estimated to expand at a CAGR of 0.5% over the forecast period. The growth is expected to be driven by new product launches, promising pipeline, increasing incidence of autoimmune diseases, and a significant rise in consumer awareness regarding Tumor Necrosis Factor (TNF).
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • TNF inhibitors are used to suppress the inflammatory response caused by TNF cytokines and hence are used for the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, Crohn’s disease, and cancer among others. The role of TNF inhibitors in the treatment of metastatic melanomas and locally advanced soft tissue sarcomas is under investigation.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • The biologics in TNF inhibitor market face a direct internal threat from biosimilars. Loss of patent exclusivities in various regions pave the way for biosimilars. In addition, the market is engaged in an intense competitive rivalry with Interleukin (IL) inhibitors. IL inhibitors have been proven to have improved safety and efficacy profiles and demonstrate superior results in several head-to-head clinical trials.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • A significant paradigm shift in the treatment of autoimmune diseases, driven by the targeted action of biologics and the emergence of biosimilars has been observed. However, the consumer demand for cost-effective medicines with improved safety and efficacy profiles is likely to have a positive impact on market dynamics.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Product Insights
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Humira led the product segment in 2018, capturing nearly half the revenue share. Humira generated USD 19.9 billion in 2018 and continues to be one of the top-selling pharmaceutical products in the world. Although Humira’s patent expired in Europe in 2018, the product retains its patent exclusivity in U.S. until 2023. The loss of patent exclusivity is likely to result in declining sales; however, Humira is projected to be at top of the TNF inhibitor products through to 2026.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • The wave of biosimilars poses a serious threat to biologics, supported by their cost-effectiveness and comparable results in head-to-head clinical trials. Several biosimilar versions of Humira, Enbrel, and Remicade have been launched. Some of the key biosimilar products included in this research are Erelzi, Inflectra/Remsima, Cyltezo, Renflexis/Flixabi, Ifixi/Zessly, Hyrimoz, and Amjevita/Amgevita.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Application Insights
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Autoimmune disease segment accounts for a majority of the market share, although the medicines are being tested for other indications, such as cancer. Rheumatoid arthritis led the application segment in 2018, capturing more than 17% of the overall revenue share. The segment is driven by a high treatment rate and product penetration for the treatment of rheumatoid arthritis.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Psoriasis and psoriatic arthritis are estimated to be the fastest growing application segments through the forecast period. Psoriasis market is driven by increasing disease prevalence, consumer awareness supported by awareness campaigns held by several public and private organizations, and favorable reimbursement policies.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Sales Channel Insights
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • TNF inhibitor drugs are commercialized through three sales channels, namely, hospital pharmacies, specialty pharmacies, and online pharmacies. Hospital pharmacies accounted for the largest market share in 2018, majorly driven by the high patient turnover in hospitals.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Most biologics and biosimilars are sold at specialty pharmacies, rather than retail pharmacies. One of the major advantages offered by specialty pharmacies is that they provide disease-specific care plans, customized for each patient, thus addressing financial constraints as well as delivering better outcomes.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Regional Insights
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • North America led the regional landscape in 2018, owing to strong commercial sales of TNF inhibitors in U.S. Some of the other factors contributing to the growth include the presence of key manufacturers, proactive government initiatives, favorable reimbursement policies, and a large patient pool.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Asia Pacific is estimated to be one of the fastest growing regions, over the forecast period. The trend of biosimilars in the emerging markets, such as China, India, and South Korea, is a key regional growth driver. In addition, the overall economic development, improvement in healthcare infrastructure, increase in disposable income, and rise in consumer awareness are likely to contribute to the regional demand.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Tumor Necrosis Factor Inhibitor Drugs Market Share Insights
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • As regulatory procedures become more stringent and competitive rivalry intensifies, new products must have a significant clinical advantage over existing products, in terms of safety and efficacy or the end result. This has led to a large number of head-to-head trials between key commercial products, such as Humira and Remicade, and new products or late-stage pipeline candidates. These trials determine the superiority of performance through a comparative analysis of several parameters.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • KEY MARKET SEGMENTS:
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • By Product
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Humira
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Enbrel
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Remicade
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Simponi/Simponi Aria
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Cimzia
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Biosimilars
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Application
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Rheumatoid Arthritis
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Psoriasis
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Psoriatic Arthritis
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Crohn’s Disease
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Ulcerative Colitis
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Ankylosing Spondylitis
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Juvenile Idiopathic Arthritis
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Hidradenitis Suppurativa
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Others
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • By Sales Channel
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Hospital Pharmacies
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Specialty Pharmacies
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Online Pharmacies
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • By Regional
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • North America
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • U.S.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Canada
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Europe
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • U.K.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Germany
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Spain
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • France
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Italy
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Asia Pacific
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Japan
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • China
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • India
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • South Korea
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Australia
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Latin America
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Brazil
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Mexico
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Argentina
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Middle East & Africa
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • South Africa
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Saudi Arabia
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • UAE
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • KEY MARKET PLAYERS
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • AbbVie Inc.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Amgen Inc.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Johnson & Johnson Services, Inc.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • UCB S.A.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Novartis International AG
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Pfizer, Inc.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Merck & co., Inc.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments

Methodology

For the Tumor Necrosis Factor Inhibitor Drugs Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Tumor Necrosis Factor Inhibitor Drugs Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Tumor Necrosis Factor Inhibitor Drugs Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Tumor Necrosis Factor Inhibitor Drugs Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

The global market for Tumor Necrosis Factor Inhibitor Drugs was estimated to be valued at US$ XX Mn in 2021.

The global Tumor Necrosis Factor Inhibitor Drugs Market is estimated to grow at a CAGR of XX% by 2028.

The global Tumor Necrosis Factor Inhibitor Drugs Market is segmented on the basis of Product, Sales Channel, Regional.

Based on region, the global Tumor Necrosis Factor Inhibitor Drugs Market is segmented into North America, Europe, Asia Pacific, Middle East & Africa and Latin America.

The key players operating in the global Tumor Necrosis Factor Inhibitor Drugs Market are sights , The global tumor necrosis factor inhibitor drugs market size was valued at USD 40.4 billion in 2018 and is estimated to expand at a CAGR of 0.5% over the forecast period. The growth is expected to be driven by new product launches, promising pipeline, increasing incidence of autoimmune diseases, and a significant rise in consumer awareness regarding Tumor Necrosis Factor (TNF). , TNF inhibitors are used to suppress the inflammatory response caused by TNF cytokines and hence are used for the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, Crohn’s disease, and cancer among others. The role of TNF inhibitors in the treatment of metastatic melanomas and locally advanced soft tissue sarcomas is under investigation. , The biologics in TNF inhibitor market face a direct internal threat from biosimilars. Loss of patent exclusivities in various regions pave the way for biosimilars. In addition, the market is engaged in an intense competitive rivalry with Interleukin (IL) inhibitors. IL inhibitors have been proven to have improved safety and efficacy profiles and demonstrate superior results in several head-to-head clinical trials. , A significant paradigm shift in the treatment of autoimmune diseases, driven by the targeted action of biologics and the emergence of biosimilars has been observed. However, the consumer demand for cost-effective medicines with improved safety and efficacy profiles is likely to have a positive impact on market dynamics. , Product Insights , Humira led the product segment in 2018, capturing nearly half the revenue share. Humira generated USD 19.9 billion in 2018 and continues to be one of the top-selling pharmaceutical products in the world. Although Humira’s patent expired in Europe in 2018, the product retains its patent exclusivity in U.S. until 2023. The loss of patent exclusivity is likely to result in declining sales; however, Humira is projected to be at top of the TNF inhibitor products through to 2026. , The wave of biosimilars poses a serious threat to biologics, supported by their cost-effectiveness and comparable results in head-to-head clinical trials. Several biosimilar versions of Humira, Enbrel, and Remicade have been launched. Some of the key biosimilar products included in this research are Erelzi, Inflectra/Remsima, Cyltezo, Renflexis/Flixabi, Ifixi/Zessly, Hyrimoz, and Amjevita/Amgevita. , Application Insights , Autoimmune disease segment accounts for a majority of the market share, although the medicines are being tested for other indications, such as cancer. Rheumatoid arthritis led the application segment in 2018, capturing more than 17% of the overall revenue share. The segment is driven by a high treatment rate and product penetration for the treatment of rheumatoid arthritis. , Psoriasis and psoriatic arthritis are estimated to be the fastest growing application segments through the forecast period. Psoriasis market is driven by increasing disease prevalence, consumer awareness supported by awareness campaigns held by several public and private organizations, and favorable reimbursement policies. , Sales Channel Insights , TNF inhibitor drugs are commercialized through three sales channels, namely, hospital pharmacies, specialty pharmacies, and online pharmacies. Hospital pharmacies accounted for the largest market share in 2018, majorly driven by the high patient turnover in hospitals. , Most biologics and biosimilars are sold at specialty pharmacies, rather than retail pharmacies. One of the major advantages offered by specialty pharmacies is that they provide disease-specific care plans, customized for each patient, thus addressing financial constraints as well as delivering better outcomes. , Regional Insights , North America led the regional landscape in 2018, owing to strong commercial sales of TNF inhibitors in U.S. Some of the other factors contributing to the growth include the presence of key manufacturers, proactive government initiatives, favorable reimbursement policies, and a large patient pool. , Asia Pacific is estimated to be one of the fastest growing regions, over the forecast period. The trend of biosimilars in the emerging markets, such as China, India, and South Korea, is a key regional growth driver. In addition, the overall economic development, improvement in healthcare infrastructure, increase in disposable income, and rise in consumer awareness are likely to contribute to the regional demand. , Tumor Necrosis Factor Inhibitor Drugs Market Share Insights , As regulatory procedures become more stringent and competitive rivalry intensifies, new products must have a significant clinical advantage over existing products, in terms of safety and efficacy or the end result. This has led to a large number of head-to-head trials between key commercial products, such as Humira and Remicade, and new products or late-stage pipeline candidates. These trials determine the superiority of performance through a comparative analysis of several parameters. , KEY MARKET SEGMENTS:, By Product, Humira , Enbrel , Remicade , Simponi/Simponi Aria , Cimzia , Biosimilars , Application, Rheumatoid Arthritis , Psoriasis , Psoriatic Arthritis , Crohn’s Disease , Ulcerative Colitis , Ankylosing Spondylitis , Juvenile Idiopathic Arthritis , Hidradenitis Suppurativa , Others , By Sales Channel, Hospital Pharmacies , Specialty Pharmacies , Online Pharmacies , By Regional, North America , U.S. , Canada , Europe , U.K. , Germany , Spain , France , Italy , Asia Pacific , Japan , China , India , South Korea , Australia , Latin America , Brazil , Mexico , Argentina , Middle East & Africa , South Africa , Saudi Arabia , UAE , KEY MARKET PLAYERS, AbbVie Inc. , Amgen Inc. , Johnson & Johnson Services, Inc. , UCB S.A. , Novartis International AG , Pfizer, Inc. , Merck & co., Inc..

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Tumor Necrosis Factor Inhibitor Drugs Market

Product ID: UCMIG35I2235

$5,300
BUY NOW GET FREE SAMPLE